{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:02:33Z","timestamp":1793826153486,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["75N93019C00065"],"award-info":[{"award-number":["75N93019C00065"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["75N93024C00056"],"award-info":[{"award-number":["75N93024C00056"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vaccine.2026.128548","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:07:15Z","timestamp":1776460035000},"page":"128548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Chikungunya virus virus-like particle vaccine (Vimkunya) induces a rapid and durable antigen-specific CD4+ T cell response"],"prefix":"10.1016","volume":"82","author":[{"given":"Fernanda H.","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimjhim","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Alexandar","family":"Escarrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Villalpando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Isela","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo","family":"Vang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Morello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Stoddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Warfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weiskopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128548_bb0005","first-page":"177","article-title":"The Newala epidemic: III. The virus: isolation, pathogenic properties and relationship to the epidemic","volume":"54","author":"Ross","year":"1956","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2026.128548_bb0010","unstructured":"WHO. Chikungunya-fact-sheets 2022."},{"key":"10.1016\/j.vaccine.2026.128548_bb0015","unstructured":"Seasonal surveillance for chikungunya virus disease in the EU\/EEA for 2025 2025. https:\/\/www.ecdc.europa.eu\/en\/chikungunya-virus-disease\/surveillance-and-updates\/seasonal-surveillance (accessed August 20, 2025)."},{"key":"10.1016\/j.vaccine.2026.128548_bb0020","unstructured":"Chikungunya virus disease worldwide overview 2025. https:\/\/www.ecdc.europa.eu\/en\/chikungunya-monthly (accessed August 20, 2025)."},{"key":"10.1016\/j.vaccine.2026.128548_bb0025","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jiw391","article-title":"chikungunya: its history in Africa and Asia and its spread to new regions in 2013-2014","volume":"214","author":"Zeller","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128548_bb0030","doi-asserted-by":"crossref","first-page":"10600","DOI":"10.1128\/JVI.01166-16","article-title":"Comprehensive genome scale phylogenetic study provides new insights on the global expansion of chikungunya virus","volume":"90","author":"Chen","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128548_bb0035","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1099\/vir.0.82714-0","article-title":"Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic","volume":"88","author":"Arankalle","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128548_bb0040","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","article-title":"Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen","volume":"17","author":"Burt","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128548_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/850ee20f-2641-46ac-b0c6-ef4ae79b6de6","article-title":"Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study","volume":"7","author":"Schilte","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128548_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008467","article-title":"A clinical scoring system to predict long-term arthralgia in Chikungunya disease: a cohort study","volume":"14","author":"de Moraes","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128548_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1038","article-title":"Fatal outcome of chikungunya virus infection in Brazil","volume":"73","author":"De Lima","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128548_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260939","article-title":"Chikungunya Death Risk Factors in Brazil, in 2017: a case-control study","volume":"17","author":"de Morais Alves Barbosa Oliveira","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128548_bb0065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1017\/S0950268808001167","article-title":"Atypical chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005\u20132006 outbreak on r\u00e9union","volume":"137","author":"Economopoulou","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2026.128548_bb0070","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fimmu.2020.00592","article-title":"Current efforts in the development of vaccines for the prevention of Zika and Chikungunya virus infections","volume":"11","author":"Schrauf","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128548_bb0075","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2026.128548_bb0080","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(25)00345-9","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Richardson","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2026.128548_bb0085","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(25)00372-1","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Tindale","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2026.128548_bb0090","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A VLP vaccine for epidemic Chikungunya virus protects non-human primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128548_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade8273","article-title":"A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans","volume":"15","author":"Raju","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128548_bb0100","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128548_bb0105","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/infdis\/jis033","article-title":"Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection","volume":"205","author":"Kam","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128548_bb0110","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.4049\/jimmunol.1300304","article-title":"An essential role of antibodies in the control of Chikungunya virus infection","volume":"190","author":"Lum","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128548_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002970","article-title":"A novel MVA vectored chikungunya virus vaccine elicits protective immunity in mice","volume":"8","author":"Weger-Lucarelli","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128548_bb0120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/imm.12992","article-title":"Human CD8 T-cell activation in acute and chronic chikungunya infection","volume":"155","author":"CNS","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2026.128548_bb0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/infdis\/jiq006","article-title":"The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation","volume":"204","author":"Wauquier","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128548_bb0130","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.1401833","article-title":"CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice","volume":"194","author":"Burrack","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128548_bb0135","doi-asserted-by":"crossref","unstructured":"Davenport BJ, Bullock C, McCarthy MK, Hawman DW, Murphy KM, Kedl RM, et al. Chikungunya virus evades antiviral CD8+ T cell responses to establish persistent infection in joint-associated tissues. J Virol 2020;94:https:\/\/doi.org\/10.1128\/jvi.02036-19. doi:https:\/\/doi.org\/10.1128\/jvi.02036-19.","DOI":"10.1128\/JVI.02036-19"},{"key":"10.1016\/j.vaccine.2026.128548_bb0140","doi-asserted-by":"crossref","unstructured":"Ware BC, Parks MG, Morrison TE. Chikungunya virus infection disrupts MHC-I antigen presentation via nonstructural protein 2 2023:2023.11.03.565436. doi:https:\/\/doi.org\/10.1101\/2023.11.03.565436.","DOI":"10.1101\/2023.11.03.565436"},{"key":"10.1016\/j.vaccine.2026.128548_bb0145","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02930-24","article-title":"Type I interferon signaling in dendritic cells limits direct antigen presentation and CD8+ T cell responses against an arthritogenic alphavirus","volume":"15","author":"Bullock","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.128548_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.101000","volume":"6","author":"Hamer","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128548_bb0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128548_bb0160","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128548_bb0165","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128548_bb0170","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128548_bb0175","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1016\/j.vaccine.2023.09.022","article-title":"A measles virus-based vaccine induces robust chikungunya virus-specific CD4+ T-cell responses in a phase II clinical trial","volume":"41","author":"Schmitz","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128548_bb0180","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/s41467-021-22036-z","article-title":"Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128548_bb0185","doi-asserted-by":"crossref","unstructured":"Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021:eabf4063. doi:https:\/\/doi.org\/10.1126\/science.abf4063.","DOI":"10.1126\/science.abf4063"},{"key":"10.1016\/j.vaccine.2026.128548_bb0190","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5+CD4+ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128548_bb0195","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.immuni.2013.09.007","article-title":"Circulating Precursor CCR7loPD-1hi CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure","volume":"39","author":"He","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128548_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00655","article-title":"Comprehensive evaluation of the expressed CD8+ T cell epitope space using high-throughput epitope mapping","volume":"10","author":"Lehmann","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128548_bb0205","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128548_bb0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/vaccines2020252","article-title":"Adjuvants in the driver\u2019s seat: how magnitude, type, fine specificity and longevity of immune responses are driven by distinct classes of immune potentiators","volume":"2","author":"Bergmann-Leitner","year":"2014","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128548_bb0215","doi-asserted-by":"crossref","unstructured":"Zheng MZM, Burmas L, Tan H-X, Trieu M-C, Lee HJ, Rawlinson D, et al. Deconvoluting TCR-dependent and -independent activation is vital for reliable Ag-specific CD4+ T cell characterization by AIM assay. Sci Adv n.d.;11:eadv3491. doi:https:\/\/doi.org\/10.1126\/sciadv.adv3491.","DOI":"10.1126\/sciadv.adv3491"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:53:54Z","timestamp":1782248034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"alternative-id":["S0264410X26003567"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128548","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chikungunya virus virus-like particle vaccine (Vimkunya) induces a rapid and durable antigen-specific CD4+ T cell response","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128548"}}